Discover a study that highlights dupilumab’s consistent efficacy in eosinophilic oesophagitis, even among patients with ...

Adults on dupilumab for severe chronic rhinosinusitis with nasal polyps had better outcomes than those who used omalizumab, ...

However, Dupilumab led to improvement in abdominal pain and iron deficiency anemia with endoscopic and histologic improvements (Table 3 and Table 4). The second patient with further jejunal ...

The day of dupilumab prescription was considered as the index date. This prescription date also represents the first time the patient receives the biologic. The baseline characteristics were assessed ...

[A]lthough our findings found that there is insufficient evidence to suggest that dupilumab use is associated with joint pain, the prevalence of joint pain observed among patients treated with ...

A new study published in the Journal of American Medical Association showed that dupilumab (Dupixent), used for treating ...

Abstract. Background: Conventional systemic corticosteroid therapy for bullous pemphigoid (BP) has been challenged due to severe adverse events.Dupilumab has emerged as an alternative therapeutical ...

Dupilumab exposure during pregnancy, up to 6 months prior to pregnancy, and during the postpartum period was assessed. Patients were matched in a 1:1 ratio with control patients based on demographics, ...

Dupilumab (Dupixent), a medicine that you get as a shot, is the first new treatment for CSU in the U.S. in over a decade. It’s already used to treat different inflammation conditions in the U.S ...

The US Food and Drug Administration (FDA) has approved dupilumab (Dupixent) as the first targeted therapy for bullous ...

Dupilumab is being jointly developed by Regeneron and Sanofi under a global collaboration agreement. To date, dupilumab has been studied across more than 60 clinical trials involving more than ...